CLOs on the Move


 
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.agios.com
  • 88 Sidney Street
    Cambridge, MA USA 02139
  • Phone: 617.649.8600

Executives

Name Title Contact Details
James Burns
Vice President, Commercial Healthcare Law and Chief Compliance Officer Profile
Bill Cook
Senior Director, Corporate Counsel Profile
Linda Hellstrom
Director, Compliance Profile
Jonathan Biller
Chief Legal Officer Profile
Jonathan Biller
Head of Legal and Corporate Affairs Profile

Similar Companies

Greenwich Hospital

A member of Yale New Haven Health System, Greenwich Hospital is a teaching institution.

Direct Success

Direct Success is a Wall Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Universal Learning Approach

Sisu Stamina is a company that offers energy chews designed to enhance physical and cognitive performance. Their products are made with potent, clean ingredients to fuel the builders of tomorrow.

BestSelf

A change for the Best is here! Child & Adolescent Treatment Services and Lake Shore Behavioral Health are proud to become BestSelf Behavioral Health!